Prothena Corporation plc

NASDAQ:PRTA   3:59:51 PM EDT
48.36
-3.12 (-6.06%)
Products, Strategic Combinations, Mergers / Acquisitions

Prothena And Novo Nordisk Announce Acquisition Agreement For Prothena’s ATTR Amyloidosis Programme

Published: 07/12/2021 11:18 GMT
Prothena Corporation plc (PRTA) - Prothena Corporation Plc - Prothena is Eligible to Receive Development and Sales Milestone Payments Totalling Up to 1.2 Billion US Dollars.
Prothena Corporation Plc - Novo Nordisk Will Develop Phase 2 Ready Antibody Prx004 for Rare Heart Disease Attr Cardiomyopathy.
Prothena Corporation Plc - Novo Nordisk Acquires Prothena's Wholly-owned Subsidiary.
Prothena Corporation Plc - Novo Nordisk Gains Rights to Intellectual Property and Related Rights of Prothena's Attr Amyloidosis Business and Pipeline.